The latest: U.S.-listed cancer drug developer I-Mab (IMAB.US) announced its board has approved a motion to pursue a listing on the Hong Kong Stock Exchange. The board also authorized the company’s senior management to proceed with related preparatory work and undertake other necessary steps for the dual listing.

Looking up: The company’s dual listings in the U.S. and Hong Kong would increase its shares’ liquidity by providing near round-the-clock trading. It would also allow the company to raise more capital to support drug research and development.

Take Note: The dual-listing means I-Mab will have primary listings in both Hong Kong and New York. But since the stock traded in one market cannot be circulated across the other, price gaps could form.

Digging Deeper: Reports that I-Mab planned to make secondary listings on the Shanghai STAR Market and in Hong Kong first emerged in August, as the company sought to attract investors in the Chinese onshore market. Some reports said I-Mab had appointed investment bank CICC as the sponsor and expected to finish the secondary listings in 2022. If the plan is fulfilled, the company would become the second to be simultaneously listed in the U.S., Hong Kong and on one of China’s A-share markets after BeiGene Ltd. (BGNE.US; 6160.HK). The latest announcement shows I-Mab’s Hong Kong listing plan is moving ahead, but no news has been given for a plan for the STAR market.

Market Reaction: I-Mab stock rose 3.8% in Tuesday trading to close at $51.23 after the news was announced.

Translation by Jony Ho

To subscribe to Bamboo Works free weekly newsletter, click here

Recent Articles

Fosun Tourism trades at all time low

Fosun Tourism’s post-Covid holiday fizzles

The resort unit of one of China’s leading conglomerates posted modest growth in the first quarter, as its broader outlook was clouded by debt issues at its parent  Key Takeaways:…

PODCAST: Ping An Trust Misses a Payment, and SAIC Sells Down Its India Venture

Ping An Trust has missed a $100 million payment on a wealth management product tied to Zhenro, a property developer. Does this show the woes afflicting China's trust industry are creeping up the food chain to top-tier names like Ping An? And leading automaker SAIC has sold 51% of its India venture to local partners for $624 million. Is this purely a commercial move, or is it also motivated by concerns about recent China-India tensions?